Legend BiotechCARTITUDE-1研究数据口头报告显示:单次输注CARVYKTI®后,三分之一的复发或难治性多发性骨髓瘤患者实现了≥5年无进展生存CARTITUDE-4亚组分析壁报展示结果表明:与标准疗法相比,在细胞遗传学风险各分组中(早在二线治疗阶段)即显示出持续且稳定的无进展生存期和总生存期获益正在进行的LB1908(治疗胃食管癌)和LB2102(治疗肺癌)的1期剂量递增研究...
Source LinkLegend BiotechCARTITUDE-1研究数据口头报告显示:单次输注CARVYKTI®后,三分之一的复发或难治性多发性骨髓瘤患者实现了≥5年无进展生存CARTITUDE-4亚组分析壁报展示结果表明:与标准疗法相比,在细胞遗传学风险各分组中(早在二线治疗阶段)即显示出持续且稳定的无进展生存期和总生存期获益正在进行的LB1908(治疗胃食管癌)和LB2102(治疗肺癌)的1期剂量递增研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.